Kornimate/medical-research-clean huggingface dataset:
educators and young people's mental health

Conditions: Mental Health Issue; Adolescent Development; Mental Health Wellness 1; Mental Health Wellness 2; Mental Disorder in Adolescence; Social Stigma

Summary: the aim of the present study is to assess the current state of mental health of educators and young persons at the education centre for health and care professions in st. gallen (bzgs) by conducting screening instruments. furthermore, the investigators aim to identify risk and protective factors for the mental health of vocational trainees in health and care professions. these results are both essential for further research and educational practice. moreover, results may maximise the chances of creating in future meaningful intervention for young persons in this specific setting.

background: young person's undergoing training in the health or social services sector are confronted with issues such as dying, illness and severe personal tragedies while they are still in the process of their own development. this can have serious effects on their mental health. during this time, vocational school is a central part of young persons' lives. the youcoment project will initiate a sustainable promotion and maintenance of mental health and thus preventively counteract the development of mental health conditions. in order to meet the special challenges of vocational schools in the health sector, this study pursues the following objectives: to assess the current state of mental health of young persons at the educational centre. to identify individual risk and protective factors for the mental health of young persons. methods: this study is the first part of the youcoment project, which will be carried out at the education centre for health and care professions in st. gallen (bzgs), switzerland between 2023 and 2026.it has approx. 150 educators. the number of trainees in basic training is about 2800. every person will be asked through the bzgs internal e-mail distribution lists to participate. beforehand, between 20 and 24 january 2023. data collection will be conducted on t1: 26 january 2023 and t2: 24 january 2025. participation in the study is voluntary. the data collection is going to be carried out using a self-administered online questionnaire. data collection will be conducted in anonymous form. the quantitative data will be analysed using descriptive and, where appropriate, exploratory statistics, as well as analysed with statistical software (spss). the statistical analyses are carried out by researchers at the university of applied sciences of eastern switzerland in st. gallen.

Eligibility criteria:
inclusion criteria: * all trainees at the centre exclusion criteria: * under age of 14

Keywords: adolescent health promotion mental health schools health literacy cross sectional educators vocational education health care profession social care professions
immunonutrition and tolerance to chemoradiotherapy in patients with head-neck cancer

Conditions: Head and Neck Cancer

Summary: the aim of the present project is to evaluate in a randomised, controlled, open-label, two parallel treatment groups pilot study, the efficacy of oral nutritional supplementation with a high-protein-high calorie mixture containing immunonutrients compared to a standard high-calorie-high-protein nutritional blend, in addition to nutritional counseling, in improving tolerance to chemoradiotherapy (ct-rt) in patients with tumours of the head and neck

in a recent study, we have shown that the systematic use of oral nutritional supplements (ons) in combination with counseling further favours the maintenance of nutrition status, the recovery of quality of life and, more importantly, improves the practicability of ct-rt. this effect would be substantially attributable to the increase in protein-energy intake associated with ons use, but also to the possible "nutraceutical" action of omega-3 fatty acids. therefore, modulation of the inflammatory response could play a role during cancer treatments. in this context, there is an already-known high-calorie-high-protein nutritional blend, enriched in immunonutrients (arginine, nucleotides and omega-3 fatty acids), which could also have an application in this type of patients. this mixture has proven effective in reducing the risk of post-operative complications (e.g. infections, fistulas, etc.) and the length of stay of patients undergoing major cancer surgery (abdominal and head and neck regions). nevertheless, in oncology, there is a growing therapeutic interest in the modulation of inflammation and immunosuppression at the tumour microenvironment level.

Eligibility criteria:
inclusion criteria: * diagnosis of head-neck cancer * indication to curative or adjuvant chemoradiotherapy * availability to planned measurements and to written informed consent. exclusion criteria: * age \<18 years * indication to or ongoing artificial nutrition * refusal

Keywords: immunonutrition chemoradiotherapy treatment tolerance nutritional counseling
a teleheath tdcs approach to decrease cannabis use

Conditions: Cannabis Use Disorder; Multiple Sclerosis

Summary: the study aims to evaluate the effect of dorsolateral prefrontal cortex (dlpfc) transcranial direct current stimulation (tdcs) in decreasing distress and cannabis use. 46 participants with relapse remitting multiple sclerosis (rrms), cannabis use disorder (cud) and elevated distress (k10 score of 10-35) will be recruited.


Eligibility criteria:
inclusion criteria: 1. ages 21-65 (inclusive) 2. seeking treatment to reduce or discontinue current cannabis use (smoke/vape/ingest) 3. current cannabis use disorder per dsm-v (mini for dsm-v) 4. k10 score 10-35, inclusive (mild to high moderate distress) 5. definite ms diagnosis, relapsing remitting (rrms) subtype 6. pdds score 0-7 (mild to moderate neurological disability, established to be able to complete procedures) 7. all medications stable for ≥ 1 month prior to enrollment and throughout the trial 8. ability to understand the informed consent process and provide consent to participate in the study 9. stable and continuous access to internet service, email (wifi "hotspot" to be provided if needed) 10. ability to use mobile devices 11. fluent in english language (due to outcomes validated in english versions only) 12. wrat-4 score ≥ 85 exclusion criteria: 1. ms clinical relapse or use of high dose of steroids in the past month 2. patients under medical marijuana use prescribed by a clinician 3. alcohol, tobacco, or substance use disorder other than cannabis 4. primary neurologic, psychiatric or other medical disorder other than ms (entry md screening) 5. currently meets dsm-v criteria for moderate or severe substance use disorder in the past 6 months for any psychoactive substance. 6. meets dsm-v criteria for current panic disorder, obsessive-compulsive disorder, post-traumatic stress syndrome, bipolar affective disorder, schizophrenia, dissociate disorders, and any other psychotic disorder or organic mental disorder 7. current suicidal ideation or deemed to be of potential risk of self-injury 8. history of traumatic brain injury 9. seizure disorder or recent (\<5 years) seizure history 10. metal implants in the head or neck 11. enrolled in group or individual therapy for substance use disorder concurrent to intervention 12. any skin disorder or skin sensitive area near stimulation locations 13. pregnant or breastfeeding
kinesio taping versus motor relearning program for upper limb

Conditions: Stroke

Summary: stroke is described as rapidly developing clinical findings of localized or generalized impairment to cerebral function, with symptoms lasting 24 hours or longer, or leading to death, with no evident cause other than a vascular origin. stroke is a prevalent and debilitating illness that affects people all around the world. stroke is the second or third largest cause of mortality in adults, as well as one of the primary causes of adult disability. because the majority of stroke patients survive the initial illness, the long-term impacts on patients and their families have the greatest influence on health. kinesiotaping is a revolutionary rehabilitation procedure. it's most typically used to treat sports injuries, however, it is progressively becoming effective in overcoming other abnormalities. kinesio tex tape brand is a flexible, thin, porous cotton fabric with an adhesive backing manufactured by dr. kenzo kase. it provides cutaneous stimulation which facilitates or limit movement, aids in the reduction of edema, reduces pain and correct joint positions for easing muscle spasms.


Eligibility criteria:
inclusion criteria: * male and female of age 18 -60 years * patients with post stroke duration of \>6 months * both ischemic and hemorrhagic stroke * modified ashworth scale of spasticity \< 3 * muscle power by manual muscle testing (mmt) ≥ 2 * no cognitive impairments by mini mental state examination (mmse) \> 24 * cortical skin sensitivity preserved (two point discrimination, barognosis, fine and crude touch) exclusion criteria: * participants failing to fall in this category would be excluded from the study. * being hospitalized due to any reason other than stroke * being subjected to treatment with botulinum toxin for \<1 year * any other condition which affects the upper extremity * contraindications for the application of kinesio taping: open wounds, skin infections such as cellulitis, allergies, skin xerosis
ha35 treatment the gingival discomfort as well as gingival redness and bleeding of patients with periodontitis

Conditions: Periodontitis

Summary: the main objective of this study is to research the treatment of 35 kda hyaluronan fragment ha35 for mild periodontitis and associated with gingival discomfort or itchiness.

in this study, tissue permeable 35 kda low molecular hyaluronan fragment ha35 was freshly manufactured using pharmaceutical grade hyaluronidase ph20 injection (state drug administration h31022111) and joint cavity ha injection (state drug administration h20174089) mixed at room temperature for 20 min. in this study, 20 patients, 8 males, and 12 females, with a mean age of 47±15 years, were selected from the outpatient clinic of the department of dentistry. all had mild periodontitis and were associated with gingival discomfort or itchiness. injection treatment was performed using freshly manufactured 35 kda hyaluronan fragment ha35. the study was an open-label clinical trial in which no information was withheld from the participating investigators. a pre- and post-treatment controlled study approach was used, whereby the investigator injected 35kda hyaluronan fragment ha35 into the periodontal pocket in a single dose of 100 mg. the distribution of injection amount was determined by the location of gingival inflammation. the clinical effects of gingival discomfort or itching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.

Eligibility criteria:
inclusion criteria: 1. mild periodontitis and associated with gingival discomfort or itchiness. 2. patient \> 18 years old. 3. systemically healthy individuals exclusion criteria: 1. patients who take anticoagulants or antiplatelet agents 2. pregnant or breastfeeding women 3. patient having expressed his opposition to participate in the research.

Keywords: 35 kda low molecular hyaluronan fragment ha35 tissue permeability intra-pocket injection gingival redness and bleeding
a safety, pilot pharmacokinetics and neurocognitive study of as-101 in combination with zidovudine in aids/arc patients

Conditions: HIV Infections

Summary: to evaluate safety, pharmacokinetics, immunologic parameters and neurocognitive data for three dosages of as-101 in combination with zidovudine (azt) in patients with aids or aids related complex (arc).


Eligibility criteria:
inclusion criteria concurrent medication: required: * zidovudine (azt). * aerosolized pentamidine for pneumocystis carinii pneumonia (pcp) prophylaxis. * allowed only with permission of the wyeth-ayerst medical monitor: * standard therapy for infections that develop during the study period. * oral acyclovir. * nystatin. * ketoconazole. * immunomodulators. * specific therapy for malignancies (including kaposi's sarcoma). patients must have the following: * diagnosis of aids or aids related complex (arc). * provide informed written consent. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * active opportunistic infection or malignancy requiring treatment at study entry. * prior history of psychiatric illness or head injury which in the judgment of the neuropsychologist would impair interpretation of the neurocognitive data. * evidence of central nervous system (cns) opportunistic infection or malignancy. * serious underlying medical problems, including insulin- dependent diabetes mellitus, unstable ashd (atherosclerotic heart disease) or uncontrolled hypertension, which may complicate interpretation of treatment results. * dementia. * evidence of = or \> 2 + proteinuria at study entry. concurrent medication: excluded without permission of the wyeth-ayerst medical monitor: * immunomodulators. * specific therapy for malignancies (including kaposi's sarcoma). patients with the following are excluded: * active opportunistic infection or malignancy requiring treatment at study entry. * prior history of psychiatric illness or head injury which in the judgment of the neuropsychologist would impair interpretation of the neurocognitive data. * evidence of conditions listed in the patient exclusion co-existing conditions. * active substance abuse. * unlikely or unable to comply with the requirements of the protocol. prior medication: excluded within 8 weeks of study entry: * immunomodulators. * antiviral therapy, except zidovudine. * excluded within 2 weeks of study entry: * intravenous or oral acyclovir. * excluded within 3 months of study entry: * ribavirin. required: * zidovudine at a dose of = or \> 1000 mg/day for at least 6 weeks prior to study entry. active substance abuse.

Keywords: drug therapy, combination acquired immunodeficiency syndrome aids-related complex ammonium trichloro(dioxoethylene-o,o'-)tellurute zidovudine
genetic effect on omega 3 fatty acids for the treatment of fatty liver disease

Conditions: Non Alcoholic Fatty Liver Disease; Steatohepatitis; Hypertriglyceridemia; Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1

Summary: to explore whether there is a different response to omega-3 fatty acid rich diet with respect to the hepatic fat fraction % (hff), triglyceride, and alt levels between the rs738409 minor allele (gg) and the common allele homozygous (cc) of pnpla3. hypothesis: we expect that subjects homozygous for the minor allele of the rs73049 snp will lower their triglyceride, hepatic fat content, and alt levels more with dietary intervention than the common allele homozygous supplementation.

nonalcoholic fatty liver disease (nafld) is emerging as one of the most common complications of childhood obesity. it is associated with and predicts the metabolic syndrome, independent of overall obesity. increased alt levels are associated with deterioration in insulin sensitivity and glucose tolerance, as well as with increasing free fatty acid (ffa) and triglyceride levels. the prevalence of metabolic syndrome and prediabetes increases with the increases in hepatic fat content in a cohort of obese adolescents. fatty liver, independent of visceral and intramyocellular lipid content plays a central role in the impairment of liver, muscle and adipose insulin sensitivity in obese adolescents. thus, fatty liver disease may be the hepatic component of the metabolic syndrome. omega 3 fatty acids lower plasma triglyceride concentrations. the subjects entering the omega diet study will be consuming an omega rich diet that is tailored to their caloric needs. this calculation is based on the patient's weight, age, and gender with the purpose of not modifying their weight at all. weight maintenance is a very important factor in this arm of the study. they will be on the diet for 12 weeks.

Eligibility criteria:
inclusion criteria: * 10 to 19 years of age * bmi equal or greater than the 95th percentile for age and gender * genotype pnpla3 cc or gg * liver mri hepatic fat fraction ≥5.5% exclusion criteria: * food allergy to fish or any components of the pills which include alpha tocopherol partially hydrogenated vegetable oils including soybean oils, gelatin, glycerol, corn or iron oxide * pregnant or breastfeeding * known bleeding disorder or coagulopathy or treatment with anticoagulant mechanisms or low platelet counts, abnormal pt or ptt * impaired glucose tolerance, type 1 or 2 diabetes * birth control pills * alcohol consumption * other liver disease * taking any medication that alters triglyceride levels, liver function, blood pressure, glucose or lipid metabolism * taking over the counter supplements that affect triglycerides or lipid metabolism including fish oil supplements * treatment for or diagnosis of thyroid disorder or have an elevated tsh at baseline * use of any antipsychotic medication * taking chronic anti-inflammatory medications * less than 100 pounds (45 kg)

Keywords: fatty liver hypertriglyceridemia elevated liver enzymes
clarithromycin v ciprofloxacin added to rifampicin + ethambutol, for opportunist mycobacterial pulmonary disease

Conditions: Pulmonary Diseases

Summary: to date key drugs in the treatment of mais, m.malmoense and m.xenopi (opportunist mycobacteria have been rifampicin and ethambutol. clarithromycin and ciprofloxacin are active in vitro against these species of mycobacteria. the primary aim of this study was to compare these to agents as supplements to rifampicin and ethambutol. a secondary aim was to assess the vale of immunotherapy with m.vaccae.


Eligibility criteria:
inclusion criteria: * patients with pulmonary disease due to m.avium intracellulare, m.malmoense or m.xenopi. aged 16 or over. with clinical and/or radiological evidence of active infection and producing sputum positive on culture on at least 2 occasions. exclusion criteria: * pregnant women and women of childbearing age not taking adequate contraceptive precautions. patients who have sputum currently positive on culture for m.tuberculosis or m.bovis. patients who have aids or who are known to be hiv positive

Keywords: pulmonary disease treatment of opportunist mycobacteria clarithromycin ciprofloxacin m.vaccae pulmonary diseases caused by opportunist mycobacteria
a metabolomic approach to probing myocardial fuel shifts in human heart failure

Conditions: Heart Failure

Summary: this proposal is designed to test the hypothesis that humans shift to reliance on ketone bodies as a cardiac fuel source during the development of hf. the investigator also propose that this shift to ketone utilization can be detected by metabolomic profiling of blood. specific aim 1: to determine if the failing human heart exhibits increased extraction of blood-borne ketone bodies. ketone bodies will be measured in coronary sinus, arterial, and central venous blood samples to determine av differences. the hf group will be comprised of patients undergoing cardiac resynchronization therapy with an implantable cardioverter-defibrillator. the control group will be compromised of patients without evidence of structural heart disease who are undergoing catheter ablation for supraventricular tachycardia. specific aim 2: to determine whether blood samples from humans with hf display metabolomic signatures indicative of increased myocardial ketone body utilization. quantitative targeted metabolomics will be performed on the samples described in aim 1 to determine if metabolite markers (e.g. c4-oh acylcarnitine, acetylcarnitine, succinate) found to be associated with increased myocardial ketone body oxidation in animal models are increased in the human hf group compared to the controls.

after subjects agree to participate in this study and are scheduled to have cardiac resynchronization therapy, the research personnel will take 1 teaspoon of blood before and after the scheduled cardiac procedure for comparison. once subjects agree to participate in this study and are scheduled to have a catheter ablation procedure, research personnel will take 1 teaspoon of blood during the scheduled cardiac procedure. these samples will be taken from catheters already placed during the scheduled cardiac procedure. blood will be sent to a lab at the sanford-burnham metabolomics core facility in orlando, florida for analysis.

Eligibility criteria:
inclusion criteria: * undergoing cardiac resynchronization therapy * undergoing sinus cannulation exclusion criteria: * nyha class ii-iv heart failure
evaluation of food additive contributions to obesity - feasibility study 3

Conditions: Obesity

Summary: the effects of food additives on body weight in humans are largely unknown. this is a feasibility study in 10 obese adults who will be followed for 5 months. eligible participants will be non-randomly assigned to 2 groups and will be taught how to limit the exposure to the studied food additives in their diet. primary outcomes in this study are recruitment rate, retention rate and adherence to the proposed dietary intervention.


Eligibility criteria:
inclusion criteria: * bmi \>/=30 kg/m2 * willingness and ability to follow the proposed dietary interventions * informed consent exclusion criteria: * previous or planned bariatric surgery in the next 1 year * current or planned participation in any structured weight-loss programs in the next 6 months * current or recent (within the last 6 months) use of weight-loss-inducing drugs or systemic steroids * excessive alcohol consumption * bipolar disorder or attention deficit hyperactivity disorder * current use of anti-depressant or anti-psychotic medications * eating disorder or any other active disorder that may lead to significant weight changes * pregnancy or planned pregnancy in the next 1 year * uncontrolled diabetes mellitus or diabetes requiring treatment with \>2 oral diabetes medications or with insulin
a combined psycho-pharmacological and brain imaging study of human sexuality

Conditions: Hypoactive Sexual Desire Disorder; Erectile Dysfunction

Summary: the current study combines a molecular genetic perspective, self report and brain imaging to the study of human sexuality in control subjects and individuals from a sexual disorder clinic. the investigators hypothesize that the variability in components of the brain dopaminergic system expressed in the mesolimbic reward system can explain variability in human sexuality, especially in desire and pleasure associated with sex.

we intend to combine molecular genetics of the dopamine receptors (d2, d3 d4 and d5) and brain imaging using 11 c raclopride in positron emission tomography (pet). 11 c raclopride is a ligand which binds to the dopamine receptor d2 and can measure dopamine release during pleasure or anticipatory reward associated with sex. the current proposal will measure changes in drd2 receptor occupancy using 11 c raclopride following explicit visual sexual desire cues in healthy control subjects and individuals who suffer from sexual dysfunction. this is in order to determine how individual genotypes modulate dopamine release in vivo in the human brain.

Eligibility criteria:
inclusion criteria: * healthy volunteers and patients * age 21-65 * male or female exclusion criteria: * psychiatric diagnosis/psychosis * neurological damage associated with loss of consciousness * infectious disease hiv * herpes * syphilis * hyperactivity treated with ritalin * pregnant women * under age

Keywords: sex brain imaging dopamine sexual disorder